PMID- 37902305
OWN - NLM
STAT- MEDLINE
DCOM- 20231124
LR  - 20240320
IS  - 1551-4005 (Electronic)
IS  - 1538-4101 (Print)
IS  - 1551-4005 (Linking)
VI  - 22
IP  - 18
DP  - 2023 Sep
TI  - EIF4A3-regulated hsa_circ_0001445 can inhibit the progression of laryngeal 
      squamous cell carcinoma via hsa-miR-432-5p-dependent up-regulation of RGMA 
      expression.
PG  - 2038-2056
LID - 10.1080/15384101.2023.2274670 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is a common malignant tumor in the head 
      and neck, the 5-year relative survival rate of patients diagnosed with laryngeal 
      cancer was estimated to be 61% from 2012 to 2018. An increasing number of studies 
      have shown that circular RNAs (circRNAs) play a key role in the occurrence and 
      development of cancer and may function as cancer biomarkers and new therapeutic 
      targets. At present, the research on the relationship between circRNAs and LSCC 
      is still in its infancy and needs further exploration. In this study, we found a 
      circRNA (hsa_circ_0001445) associated with LSCC based on bioinformatics analysis. 
      Quantitative real-time polymerase chain reaction (qRT-PCR) assay indicated that 
      the expression of hsa_circ_0001445 was down-regulated in LSCC tissues and cell 
      lines. Notably, the expression of hsa_circ_0001445 was negatively correlated with 
      aggressive clinicopathological features and poor prognosis. Then, functional 
      experiments found that overexpression of hsa_circ_0001445 inhibited the 
      proliferation, migration and invasion of LSCC cells and tumor growth in vivo. 
      Mechanistically, RNA immunoprecipitation (RIP), biotin-labeled probe pull-down, 
      luciferase reporter assay and western blot experiments were employed and found 
      that EIF4A3 reduced the expression of hsa_circ_0001445, and the direct binding of 
      hsa_circ_0001445 to hsa-miR-432-5p attenuated the inhibitory effect of 
      hsa-miR-432-5p on RGMA. In summary, our research suggests that hsa_circ_0001445 
      may be used as a potential prognostic biomarker and therapeutic target for LSCC.
FAU - Yu, Miaomiao
AU  - Yu M
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Cao, Huan
AU  - Cao H
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Yang, Jianwang
AU  - Yang J
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Liu, Tao
AU  - Liu T
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Gao, Jiaxue
AU  - Gao J
AD  - Department of Otorhinolaryngology, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, China.
FAU - Wang, Baoshan
AU  - Wang B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231123
PL  - United States
TA  - Cell Cycle
JT  - Cell cycle (Georgetown, Tex.)
JID - 101137841
RN  - 0 (MIRN432 microRNA, human)
RN  - 0 (RNA, Circular)
RN  - 0 (MicroRNAs)
RN  - EC 3.6.1.- (EIF4A3 protein, human)
RN  - EC 2.7.7.- (Eukaryotic Initiation Factor-4A)
RN  - EC 3.6.4.13 (DEAD-box RNA Helicases)
SB  - IM
MH  - Humans
MH  - RNA, Circular/genetics/metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/genetics
MH  - Up-Regulation/genetics
MH  - Cell Line, Tumor
MH  - *MicroRNAs/genetics/metabolism
MH  - Cell Proliferation/genetics
MH  - *Head and Neck Neoplasms
MH  - Gene Expression Regulation, Neoplastic
MH  - Eukaryotic Initiation Factor-4A/genetics
MH  - DEAD-box RNA Helicases/metabolism
PMC - PMC10761152
OTO - NOTNLM
OT  - EIF4A3
OT  - Laryngeal squamous cell carcinoma
OT  - RGMA
OT  - hsa-miR-432-5p
OT  - hsa_circ_0001445
COIS- No potential conflict of interest was reported by the authors.
EDAT- 2023/10/30 12:42
MHDA- 2023/11/24 06:42
PMCR- 2024/11/23
CRDT- 2023/10/30 08:53
PHST- 2024/11/23 00:00 [pmc-release]
PHST- 2023/11/24 06:42 [medline]
PHST- 2023/10/30 12:42 [pubmed]
PHST- 2023/10/30 08:53 [entrez]
AID - 2274670 [pii]
AID - 10.1080/15384101.2023.2274670 [doi]
PST - ppublish
SO  - Cell Cycle. 2023 Sep;22(18):2038-2056. doi: 10.1080/15384101.2023.2274670. Epub 
      2023 Nov 23.